RAPID DETECTION OF MYCOPLASMA CONTAMINATION IN CELL CULTURE SAMPLES

• US 20110104686A1
• Filed: 10/29/2010
• Published: 05/05/2011
• Est. Priority Date: 10/29/2009
• Status: Abandoned Application

• Current Assignee: Bio-Rad Laboratories Incorporated
• Original Assignee: Bio-Rad Laboratories Incorporated
• Inventors: Ugozzoli, Luis A., Litterst, Claudia
• Application Number:
  US12/915,485
• Publication Number:
  US 20110104686A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/689 for bacteria
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers

Abstract

The present invention provides for methods of detecting mycoplasma, for example in cell culture media.

Claims

1. A method of detecting mycoplasma in a cell culture media, the method comprising,

obtaining an aliquot of cell culture media;

performing a real-time nucleic acid amplification reaction with a thermostable DNA polymerase to amplify a mycoplasma nucleic acid, if present, in the aliquot wherein;

nucleic acids in the aliquot are not further purified, and

the amplification reaction comprises an intercalating fluorescent dye that produces a fluorescent signal in the presence of double stranded DNA; and

detecting a melting temperature of an amplification product of the amplification reaction, wherein the presence of an amplification product indicates the presence of mycoplasma in the cell culture.

2. The method of claim 1, wherein the amplification reaction is capable of amplifying any of Mycoplasma arginini, M. pirum, M. hominis, M. fermentans, M. salivarium, M. orale, M. hyorhinis and Acholeplasma laidlawii, if present in the aliquot.

3. The method of claim 1, wherein the mycoplasma nucleic acid comprises a portion of at least 50 nucleotides of a rpoB gene.

4. The method of claim 1, wherein the performing step comprises amplifying the portion with the following degenerate primers:

5. The method of claim 4, wherein the reaction contains no more primers than one forward primer and one reverse primer.

6. The method of claim 1, wherein the detecting step further comprises nucleotide sequencing the amplification product and correlating the determined nucleotide sequence to nucleotide sequences of different mycoplasma species, thereby determining the identity of the mycoplasma.

7. The method of claim 1, wherein the amplification reaction does not comprise a detectably-labeled oligonucleotide.

8. The method of claim 1, wherein the polymerase is linked to a sequence non-specific DNA binding domain.

9. The method of claim 8, wherein the sequence non-specific DNA binding domain is an Sso7 DNA binding domain.

10. The method of claim 1, wherein the aliquot comprises a sufficient amount of an amplification inhibitor to inhibit activity of Taq polymerase by at least 10%.

11. The method of claim 10, wherein the inhibitor is selected from the group consisting of cell debris, cell waste products (e.g., polysaccharides or proteins), and fetal bovine serum or an amplification inhibitor component thereof.

12. The method of claim 1, wherein the amplification reaction comprises a sufficient amount of an osmolyte and/or heparin to improve efficiency of the amplification reaction.

13. The method of claim 12, wherein the osmolyte is selected from the group consisting of sarcosine, trimethylamine N-oxide (TMAO), dimethylsulfoniopropionate, and trimethylglycine.

14. A method of detecting mycoplasma in a cell culture media, the method comprising,

obtaining an aliquot of cell culture media;

performing a nucleic acid amplification reaction with a DNA polymerase to amplify a mycoplasma nucleic acid, if present, in the aliquot wherein;

(a) the performing step comprises amplifying the portion with a first and second primer, the first primer comprising the following degenerate sequence;

GAAGAWATGCCWTATTTAGAAGATGG (SEQ ID NO;

1); and

the second primer comprising the following degenerate sequence;

CCRTTTTGACTYTTWCCACCMAGTGGTTGTTG (SEQ ID NO;

2), wherein W represents A or T, Y represents C or T, R represents A or G, and M represents A or C; and

(b) detecting the presence or absence of an amplification product of the amplification reaction, wherein the presence of an amplification product indicates the presence of mycoplasma in the cell culture.

15. The method of claim 14, wherein the amplification reaction is monitored in real-time.

16. The method of claim 15, wherein the amplification reaction comprises an intercalating fluorescent dye that produces a fluorescent signal in the presence of double stranded DNA at least twice that produced in the presence of single-stranded DNA only.

17. The method of claim 14, wherein the first and second primers consist of the following degenerate sequences, respectively:

18. The method of claim 14, wherein nucleic acids in the aliquot are not further purified.

19. The method of claim 14, wherein the reaction contains no more than one forward and one reverse primer designed to hybridize to an rpoB gene.

20. The method of claim 14, wherein the detecting step further comprises nucleotide sequencing the amplification product and correlating the determined nucleotide sequence to nucleotide sequences of different mycoplasma species, thereby determining the identity of the mycoplasma.

21. The method of claim 14, wherein the amplification reaction does not comprise a detectably-labeled oligonucleotide.

22. The method of claim 14, wherein the polymerase is linked to a sequence non-specific DNA binding domain.

23. The method of claim 22, wherein the sequence non-specific DNA binding domain is an Sso7 DNA binding domain.

24. The method of claim 14, wherein the amplification reaction comprises a sufficient amount of an osmolyte and/or heparin to improve efficiency of the amplification reaction.

25. The method of claim 24, wherein the osmolyte is selected from the group consisting of sarcosine, trimethylamine N-oxide (TMAO), dimethylsulfoniopropionate, and trimethylglycine.

26. A kit for amplifying mycoplasma DNA, if present, from cell culture media, the kit comprising:

a first degenerate primer comprising GAAGAWATGCCWTATTTAGAAGATGG (SEQ ID NO;

1); and

a second degenerate primer comprising CCRTTTTGACTYTTWCCACCMAGTGGTTGTTG (SEQ ID NO;

2),

wherein W represents A or T, Y represents C or T, R represents A or G, and M represents A or C.

27. The kit of claim 26, wherein the first primer consists of GAAGAWATGCCWTATTTAGAAGATGG (SEQ ID NO:

1); and

the second primer consists of CCRTTTTGACTYTTWCCACCMAGTGGTTGTTG (SEQ ID NO;

2).

28. The kit of claim 26, further comprising at least one or more of the following:

a polymerase;

an intercalating fluorescent dye;

a positive control polynucleotide comprising a polynucleotide that can be amplified by a polymerase primed by SEQ ID NO;

1 or SEQ ID NO;

2.

29. The kit of any of claims 26-28, wherein the kit further comprises a positive control sample comprising a nucleic acid comprising at least 50 contiguous nucleotides of a Mycoplasma rpoB gene.

30. The kit of claim 26, further comprising an osmolyte and/or heparin.

31. The kit of claim 30, wherein the osmolyte is selected from the group consisting of sarcosine, trimethylamine N-oxide (TMAO), dimethylsulfoniopropionate, and trimethylglycine.

32. The kit of claim 28, wherein the polymerase is linked to a sequence non-specific DNA binding domain.

33. The kit of claim 32, wherein the sequence non-specific DNA binding domain is an Sso7 DNA binding domain.